Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kymera Therapeutics's Enterprise Value is $1,376.54 Mil.
Kymera Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-223.61 Mil. Therefore, Kymera Therapeutics's EV-to-EBIT ratio for today is -6.16.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kymera Therapeutics's Enterprise Value is $1,376.54 Mil.
Kymera Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-216.24 Mil. Therefore, Kymera Therapeutics's EV-to-EBITDA ratio for today is -6.37.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kymera Therapeutics's Enterprise Value is $1,376.54 Mil.
Kymera Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $47.07 Mil. Therefore, Kymera Therapeutics's EV-to-Revenue ratio for today is 29.24.
Kymera Therapeutics Enterprise Value Historical Data
The historical data trend for Kymera Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kymera Therapeutics's Enterprise Value
For the Biotechnology subindustry, Kymera Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kymera Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Kymera Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Kymera Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics (NAS:KYMR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Kymera Therapeutics's current Enterprise Value is $1,376.54 Mil.
Kymera Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-223.61 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Kymera Therapeutics's current Enterprise Value is $1,376.54 Mil.
Kymera Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-216.24 Mil.
Kymera Therapeutics's current Enterprise Value is $1,376.54 Mil.
Kymera Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.07 Mil.
Kymera Therapeutics's current Enterprise Value is $1,376.54 Mil.
Kymera Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-207.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Kymera Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KYMR has been successfully added to your 